GNLX - NASDAQ

Genelux Corporation

GNLX·NASDAQ

$3.05

+2.7%

HealthcareBiotechnology

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$114.73M

EPS-0.8600

P/E Ratio-3.55

Earnings Date08/06/2026

gnlx

Cash and Short Term Investments

Last Annual Value

14.60M

3-Year CAGR

233%

5-Year CAGR

10-Year CAGR

42%

Adjust for Inflation

Genelux Corporation Competitors Analysis of Cash and Short Term Investments

GNLX · NASDAQ

Company	Cash and Short Term Investments	CAGR 3Y	CAGR 5Y	CAGR 10Y
Genelux Corporation NASDAQ:GNLX	14.60M	-14.3%	26.6%	N/A
Aldeyra Therapeutics, Inc. NASDAQ:ALDX	70.04M	-21.1%	-21.1%	10.9%
Codexis, Inc. NASDAQ:CDXS	78.21M	6.3%	-7.7%	15.1%
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP	163.94M	98.7%	10.9%	27.0%
Invivyd, Inc. NASDAQ:IVVD	226.69M	4.2%	-17.5%	N/A
OmniAb, Inc. NASDAQ:OABI	54.02M	-14.7%	N/A	N/A
Pyxis Oncology, Inc. NASDAQ:PYXS	66.86M	-17.6%	-24.6%	N/A
SELLAS Life Sciences Group, Inc. NASDAQ:SLS	71.89M	205.2%	27.4%	14.8%
Candel Therapeutics, Inc. NASDAQ:CADL	119.73M	50.1%	7.7%	N/A
Lexeo Therapeutics, Inc. Common Stock NASDAQ:LXEO	181.77M	14.4%	6.0%	N/A
Contineum Therapeutics, Inc. Class A Common Stock NASDAQ:CTNM	262.90M	28.1%	30.7%	N/A

Genelux Corporation Fair Value Envelope

GNLX · NASDAQ

Our analysis suggests that GNLX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.05, this represents a potential HIDDEN relative to our calculated worth for Genelux Corporation.

HIDDEN

Intrinsic Value

Current Price: $3.05

Related Guides

Blog Categories

Continue your GNLX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.